As part of our commitments around sustainability, Sanofi include carbon reduction plans in our NHS tenders, at the same time as tackling climate change and accelerating the reduction of our own environmental impact across the business.

Sanofi launched the Repen programme in 2024. This pilot programme forms part of Sanofi’s commitment to environmental protection. The used pens are posted back for recycling, free of charge to be recycled into metal, glass and plastic furniture.&nbsp;
Read more on the Repen recycling initiative that saves thousands of tonnes of waste each year.

RePen Programme

black

Get in Touch with the Health System Solutions Team

The NHS is one of the world's first healthcare systems to explicitly put sustainability in its targets which we are supporting in numerous ways.

Let’s Be Sustainable

OUT-OF-TAXONOMY

PAYOR

<a href="${link:{uuid:{3c621072-b317-4715-bb3e-c63ceb933735},repository:{dam},path:{/Portal/UK/Prescribing-links/Dupixent-AD-and-PN-GB-PI.pdf}}}">Dupixent (dupilumab) Prescribing Information UK</a>
Explore our Expert Encounter series focused on Atopic Dermatitis. Uncover new strategies for managing comorbidities, learn about the latest evidence supporting disease-modifying therapies, and gain practical guidance for implementing these approaches in your clinical practice.
<h3>Exploring Disease Modification in Atopic Dermatitis: Insights from International Experts</h3>

In this enlightening Q&amp;A session, dermatology experts Professor Cork and Professor Thaçi share their valuable insights on the evolving landscape of Atopic Dermatitis treatment, with a focus on disease modification.
These videos offer valuable perspectives for Dermatologists and healthcare professionals seeking to optimise their approach to managing atopic dermatitis, particularly in cases where traditional treatments have not provided adequate control.

<h3>The Paradigm Shift in Atopic Dermatitis Management: From Control to Disease Modification</h3>

A Sanofi sponsored symposium presented at the British Association of Dermatologists Annual Meeting, July 2025
This symposium, chaired by Dr. Andrew Pink, featured insights from Professor Michael Ardern-Jones and Professor Diamant Thaçi on the evolving landscape of atopic dermatitis (AD) management. The experts discussed the transition from symptom control to disease modification in AD treatment.

Key topics included strategies for managing AD comorbidities, with a focus on ocular complications, and the latest evidence supporting the disease modification potential of targeted therapies. The faculty presented the latest data on sustained clinical control, barrier restoration, and the impact of treatment on growth, microbiome normalisation, and nerve fibre density in AD patients.
The symposium highlighted the importance of early intervention to potentially reduce cumulative life course impairment in AD. Practical guidance was provided for implementing disease-modifying therapies in clinical practice, including monitoring and managing treatment-related effects.
This paradigm shift in AD management emphasises long-term strategies for moderate-to-severe cases, aiming to alter the disease course beyond symptom control. The full recording offers in-depth discussions on these critical developments in AD care.

<h3 style="text-align:center;">Discover other resources &nbsp;</h3>

Expert Insights on Advancing the Conversation on Disease Modification in Atopic Dermatitis

DUPIXENT (dupilumab) Prescribing Information UK

SPECIALTY-CARE

DUPIXENT

ATOPIC-DERMATITIS

DERMATOLOGY

<a href="${link:{uuid:{3c621072-b317-4715-bb3e-c63ceb933735},repository:{dam},path:{/Portal/UK/Prescribing-links/Dupixent-AD-and-PN-GB-PI.pdf}}}">Dupixent (dupilumab) Prescribing Information UK</a>

DE:RM is Sanofi’s flagship annual promotional meeting, bringing together healthcare professionals from across the UK who are dedicated to the care of people living with atopic dermatitis (AD). Curated in collaboration with expert Chairs in AD management, DE:RM offers a balanced, one-day agenda featuring diverse speakers and discussion topics. The meeting explores the evolving treatment landscape, including the appropriate use of Dupixent (dupilumab) and other biologic therapies. DE:RM is designed to foster clinical excellence, collaboration, and innovation in dermatology.

<h2>Understanding Atopic Dermatitis in Skin of Colour – Teena Mackenzie</h2>

In this insightful video, Nurse Consultant Teena Mackenzie explores the unique challenges and considerations in diagnosing and treating atopic dermatitis (AD) in patients with skin of colour. Drawing from clinical experience and educational initiatives, she highlights the importance of accurate assessment, cultural sensitivity, and holistic care. The session also covers EASI scoring nuances, pigmentation differences, and the impact of underrepresentation in dermatology education and research.

<h2>Type 2 Inflammation Panel Discussion</h2>

This engaging panel discussion brings together leading dermatology and respiratory experts to explore the complexities of type 2 inflammation across multiple comorbidities, including atopic dermatitis, asthma, and eosinophilic esophagitis. Through a real-world case study of a 17-year-old patient, the panel highlights the importance of integrated care, biomarker-driven treatment decisions, and the role of DUPIXENT in managing type 2 inflammatory conditions. A must-watch for anyone looking to deepen their understanding of holistic patient management and the evolving treatment landscape.

<h2 style="text-align: center;">Discover other resources 
 &nbsp;</h2>

DE:RM – Dermatology Excellence: Redefining Management

Explore our dedicated podcast series focused on atopic dermatitis, featuring expert insights, patient perspectives, and the latest clinical thinking around Dupixent. Each episode dives into key topics such as disease pathophysiology, treatment strategies, real-world experiences, and evolving standards of care. Whether you're a healthcare professional, researcher, or simply curious about dermatological innovation, this series offers a rich, accessible resource to stay informed and inspired.

<h2>Dr Hywel Cooper Podcast on AD AND THE IMPACT ON PATIENTS QUALITY OF LIFE (QOL)</h2>

In this insightful episode, Dr Hywel Cooper, Consultant Dermatologist and Research Lead at Portsmouth Hospital, explores the profound impact of atopic dermatitis on patients’ quality of life. From the challenges of hand eczema and sleep disruption to the emotional toll on families and the importance of personalised care, Dr Cooper shares clinical experience and practical strategies for improving outcomes. A must-listen for healthcare professionals seeking to understand the lived experience of AD.

<h2>Dr Antonia Lloyd-Lavery Podcast - TACKLING THE COMORBIDITIES ASSOCIATED WITH AD</h2>

In this episode, Dr Antonia Lloyd-Lavery, Consultant Dermatologist at Oxford University Hospitals, discusses the often-overlooked comorbidities associated with atopic dermatitis (AD). From asthma and allergic rhinitis to ocular complications, Dr Lloyd-Lavery shares her clinical insights on holistic patient assessment, and the importance of personalised care. A valuable listen for healthcare professionals aiming to optimise long-term outcomes for patients aged 12+ with moderate-to-severe AD.

<h2>Dr Gabriela Petrof Podcast - AD IN PAEDIATRIC PATIENTS</h2>

In this episode, Dr Gabriela Petrof, Consultant Dermatologist at Great Ormond Street Hospital, shares her expertise in treating paediatric patients with severe atopic dermatitis. She discusses the unique challenges of managing AD in children and adolescents, the importance of family dynamics, and the evolving treatment landscape-including the role of biologics and timely intervention. A thoughtful and compassionate look at how personalised care can improve outcomes and quality of life for young patients and their families.

<h2>Dr Andrew Pink podcast – UPCOMING HEAD-to-HEAD TRIALS FOR AD</h2>

Dr Andrew Pink, Consultant Dermatologist at Guy’s and St Thomas’ Hospital, joins the podcast to discuss the evolving treatment landscape in atopic dermatitis and the importance of comparative data. He introduces the BEACON trial, a UK-wide, multi-arm study comparing systemic therapies including dupilumab, methotrexate, and ciclosporin, and shares insights on trial design, patient monitoring, and multidisciplinary care. A must-listen for clinicians navigating treatment options and seeking evidence-based clarity in AD management.

<h2>Dr Richard Woolf podcast– TARGETED THERAPIES FOR AD</h2>

Dr Richard Woolf, Consultant Dermatologist and Clinical Lead at Guy’s and St Thomas’, shares his expert perspective on the evolving role of targeted therapies in the management of atopic dermatitis. From real-world experience with biologics like dupilumab and tralokinumab to collaborative care with ophthalmology and navigating NICE guidance, Dr Woolf offers practical insights into treating high-impact sites and improving patient pathways. A valuable listen for clinicians seeking clarity on treatment options and multidisciplinary best practices in AD care.

Inside Atopic Dermatitis: The Dupixent (Dupilumab) Podcast Series

<a href="${link:{uuid:{cf1f3311-de33-48bd-a469-b9f8adafc603},repository:{dam},path:{/Portal/UK/Prescribing-links/Nexviadyme-PI-GB-November-2022-v2.pdf}}}" style="color: rgb(122 0 230) !important;">Nexviadyme ▼ (avalglucosidase alfa) prescribing information UK</a>

<h2>Details</h2>
Click below to enter the website for patients in Britain who have been prescribed Nexviadyme, or their caregiver.

RARE-DISEASE

LUMIZYME

NEXVIAZYME

MYOZYME

POMPE

NEXVIADYME 
 avalglucosidase alfa

<table border="1" cellpadding="1" cellspacing="1" style="width:100%;">
 <tbody>
 <tr>
 <td>
 &nbsp;
 MAT-XU-2203480 (v11.0) 
 Date of preparation: January 2025</td>
 </tr>
 </tbody>
</table>

Website with information for patients prescribed Nexviadyme

Nexviadyme®▼ (avalglucosidase alfa) patient and caregiver website

Nexviadyme®▼(avalglucosidase alfa) prescribing information UK

To read this content, please activate your Sanofi Campus account via the email we've sent to you.

If you didn't receive our first email at {email} to confirm your account you can request a new one below. If you don't see it, you may need to check your spam folder.

title

In order to see relevant content, tell us what you are interested in

Title

Quick Summary

This website is for healthcare professionals only.

Welcome to BP Sanofi Campus

Create new password

complete your profile to help us provide you with content that's relevant to you.

Your profile is incomplete

Development of ADCT involved literature review as well as interviews with patients and physicians, and was funded by Sanofi and Regeneron.

The ADCT gives a measure of how controlled your patient’s eczema is. Use these 6 concise questions to evaluate all dimensions of atopic dermatitis control.

Atopic dermatitis, a type of eczema, may be affecting your patient’s life in more ways than you know.

Enjoy more exclusive content{newline}by <a>registering today</a>

MAT-XU-2300297 (v3.0) - Date of preparation: October 2023

MAT-XU-2305062 (v1.0) - Date of preparation: November 2023

MAT-XU-2300297 (v3.0) Date of Preparation: October 2023

MAT-XU-2305047 (v1.0) - Date of preparation: November 2023

Already have an account? <a>Sign in here</a>

Best practices on optimising patient care

Get a customised view of the topics that you're interested in, along with the ability to save content to watch or read at a later date.

Unlimited access to premier content, white papers, case studies, research papers, webinars, training, and up-to-date scientific medical resources.

Personalised content based on your areas of interest

Connect and stay up-to-date with peers in your area of speciality and topics of interest through free events and leadership forums.

Please sign in to continue and read the full article

Please sign up to continue reading the full article.

We respect your privacy and will not share your information with any 3rd parties.

Topical guides written specifically for patients

Unlimited access to the latest patient guide guides and resources. Share content with your patients with easy-to-use online tools.

Please complete your profile to read the content.

Your profile is not validated yet. Please verify your inbox.

Restricted Access

Share via {platform} (opens email client)

Cause And Symptoms

Complications

Diagnosis And Treatment

Overview

Prevention

References

We can't find the page you're looking for

You are going to a website that is not operated by Sanofi. Sanofi has no control over the content or availability of linked sites or resources, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them. Please ensure that you read the legal and privacy policy sections of any third-party site to which you link.

You are about to leave Sanofi Campus website.

You are now leaving this site to visit a partner website.

Thank you for visiting COPD Sanofi Campus.

Welcome to COPD Sanofi Campus.

Welcome to COPD Sanofi Campus

Welcome to CSU Sanofi Campus

Please refresh the page to access the content

Sorry, something went wrong

The page you are looking for may be under maintenance, or the link may be incorrect.

Sorry, we can't find this page

There are no upcoming events

Showing {start}–{end} of {total} events

Event details

Check back later for upcoming events, or browse all available events across therapeutic areas.

There are no events scheduled for this therapeutic area

Something went wrong

Try a different keyword, date range, or venue.

No matching events

Registration information

Success! We've received your request

You are going to a website that is not operated by Sanofi or a Sanofi website where the terms of use may differ. For external websites, Sanofi has no control over the content or availability of linked sites or resources, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them. Please ensure that you read the legal and privacy policy sections of any third-party or Sanofi sites.

You are about to leave Sanofi campus website.

You are about to leave Campus.sanofi/uk.

Privacy Notice Update | We have updated our Privacy Notice for Healthcare Professionals to improve your experience collaborating with us, maintain high standards of privacy and ultimately strengthen the trust you place in us. Key improvements include enhanced clarity on why and how Sanofi processes your personal data.

Thank you for registering. Before we get started, we need to confirm your email address to ensure that we have the correct information.

Please follow these steps to complete your registration:

Would you like to receive future text messages about Beyfortus updates?

Sanofi is here to help support your patients, their families, and caregivers. For more information regarding Beyfortus® (nirsevimab-alip) Injection, call <a.callPhoneNumberBeyfortus>1-855-BEYFORTUS (1-855-239-3678)</a.callPhoneNumberBeyfortus> or sign up below to receive the latest updates via email. All fields are required.

Would you like to learn more about Beyfortus® (nirsevimab-alip) 50 mg and 100 mg injection? Leave us your contact details, and a Sanofi representative will be in touch. All fields are required.

Would you also like to receive future messages and updates about Beyfortus?

Do you want to participate in the Beyfortus Reservation Program?

What information are you interested in learning more about? (Optional)

Are you enrolled in CENRIFKI REMS?

Request a visit from your local ALPROLIX representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Request a visit from your local ALTUVIIIO representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Request a visit from your local QFITLIA representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Sign up to schedule an office visit with your ALPROLIX® Representative or receive updates about ALPROLIX. Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Sign up to schedule an office visit with your local Sanofi representative and/or to receive updates about Qfitlia. Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required (unless otherwise specified).

All fields are required. (unless otherwise specified)

Title should not exceed 100 characters

Enter your title

This site is intended for UK healthcare professionals only and contains information on Sanofi UK's medicines, educational resources and more. Please click the appropriate button below. By entering this site, you are confirming that you are a UK healthcare professional. This site contains promotional information. Some content may only be relevant to HCPs practising in Great Britain (England, Scotland and Wales) according to product availability. This website is optimised for desktop use, and some features may perform differently on mobile devices.

MAT-XU-2300297 (v7.0) - Date of Preparation: July 2025

Welcome to Sanofi Campus UK

Welcome to ITP Sanofi Campus

This content is only available to registered users. Please sign in or register to view this content.

Please Sign In

Review the materials in your cart before checkout.

Browse and order materials for your practice.

Filters

Materials

Cart

Checkout

Email verification

You're seeing a preview of the portal. Clear your cookies (by closing your browser window for example) to go back to public mode.

We've updated our privacy notice to better protect your data and enhance your experience. Please take a moment to review the changes by <privacyNewTab>clicking here</privacyNewTab>. Your privary matters for us. Please click on continue to confirm you have read the new privacy notice.

Privacy Notice Update

Communication consent

My Consent

Password

Confirm password

{resultsCount, plural, one {result} other {results}}

Please sign in to access to the results

You need to sign-in to your account in order to access medical content.

To access the results, please register in under 1 minute

You are now leaving the Sanofi content section of our site and entering the external medical bibliographic search content section.

You are entering to the External Scientific Content Site

You are now leaving the external medical bibliographic search section of our site and entering the Sanofi content section.

Latest Resources

Let’s Be Sustainable

Expert Insights on Advancing the Conversation on Disease Modification in Atopic Dermatitis

DE:RM – Dermatology Excellence: Redefining Management

Inside Atopic Dermatitis: The Dupixent (Dupilumab) Podcast Series

Nexviadyme®▼ (avalglucosidase alfa) patient and caregiver website